bertilimumab + prednisone

**bertilimumab + prednisone** is an investigational combination therapy evaluated for the treatment of moderate-to-extensive bullous pemphigoid. Bertilimumab is a first-in-class, human monoclonal antibody targeting the chemokine eotaxin-1 (CCL-11), thereby blocking eosinophil migration and activation in inflammatory pathways. Prednisone is a synthetic glucocorticoid corticosteroid widely used for its anti-inflammatory and immunosuppressive effects. In clinical trials, bertilimumab is administered intravenously alongside low and rapidly tapered doses of oral prednisone, aiming to reduce corticosteroid exposure while achieving disease control. This combination leverages bertilimumab's targeted immunomodulation and prednisone's broad suppression of acute inflammation.